



Targeting enteroviral 2A protease by a 16-mer synthetic peptide: Inhibition of 2Apro_o induced apoptosis in a stable Tet-on HeLa cell line

Nader Maghsoudi^{a,*}, Narges Kh. Tafreshi^{a,b}, Fariba Khodaghola^a, Zahra Zakeri^c, Mitra Esfandiari^c,
Hamid Hadi-Alijanvand^c, Marjan Sabbaghian^d, Amir Hossein Maghsouli^a, Mahnaz Sajadi¹,
Mastaneh Zohri^e, Maryam Moosavi^f, Mehdi Zeinoddini¹¹

^a Neuroscience Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran
¹¹ Lee Moffitt Cancer Center, Tampa, FL, USA

^b Department of Biology, Queens College and Graduate Center of the City University of New York, Flushing, NY, USA

^c Child Family Research Institute, Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, Canada

^d Institute of Biomedical and Biophysics, University of Tehran, Tehran, Iran

^e Department of Biology, Tofigh Daru Co., Tehran, Iran

^f Department of Physiology and Neuroscience Research Center 1, Shiraz University of Medical Sciences, Shiraz, Iran

¹¹ School of basic science, Tarbiat Modares University, Tehran, Iran

ARTICLE INFO

Available online 22 September 2009
Received 11 October 2009
Accepted 15 December 2009
Available online 22 January 2010

Keywords:
CVB3
2A protease
Apoptosis

Classification

ABSTRACT

Enteroviridae such as Coxsackievirus are important infectious agents causing viral heart diseases. Viral protease 2A (2A^{pro}) initiates the virus life cycle and is an excellent target for developing antiviral drugs. Here, to evaluate the validity of the 2A^{pro} as a proper therapeutic target, and based on the existing information and molecular dynamics, a 16-mer peptide was designed to specifically target the active site of protease 2A^{pro} in order to block its activity of CVB3 2A^{pro}. We showed that the peptide could compete with endogenous substrate in a concentration-dependent manner. Further, we established a HeLa cell line that expressed 2A^{pro}. Expression of 2A^{pro} resulted in significant morphological alteration and eventual cell death. Western blot and viability assay showed that the 16-mer peptide (200 µg/ml) could significantly block 2A^{pro} activity and its cytotoxic effect. Future modification of the 16-mer peptide could improve its affinity for 2A^{pro} and therefore develop effective antiviral drug.

© 2009 Elsevier Inc. All rights reserved.

Introduction

Coxsackievirus 83 (CVB3) is considered as the most important infectious agent that can cause severe heart complications. CVB3 is associated with both acute and chronic forms of myocarditis (inflammation of the myocardium), a life-threatening disease (Reyes and Lerner, 1985; Woolf, 1980). Chronic forms of this disease may lead to dilated cardiomyopathy (DCM), for which the only available and effective treatment is the highly cost heart transplantation procedure. Enteroviruses, in general, and CVB3, in particular, are responsible for causing up to 30–45% of acute forms of myocarditis and 25% of DCM (Bowles et al., 1985; Frisk et al., 1984). In an infected cardiomyocyte, cleavage of dystrophin by viral 2A^{pro} is considered an important mechanism for CVB3-induced cardiac injury (Badoiff et al., 1999). CVB3 infection is also associated with programmed cell death

and apoptosis in myocardial tissue (Coldstau et al., 2000; Olivetti et al., 1997).

CVB3 is a picornavirus, a family of small positive-stranded RNA viruses associated with a large variety of human and animal diseases. Following virus entry, viral RNAs are translated, and newly synthesized viral proteins are released within the cytoplasm of infected host as large polyprotein, which will be then processed and further cleaved by virus-specific protease 2A and 3C to generate mature structural and nonstructural viral proteins (Larsen and Wimmer, 1988; Skelton and Liebig, 1994). Viral replication depends on this proteolytic cleavage. Although the newly synthesized viral polyprotein is processed mainly by 3C^{pro}, the primary cleavage event separating the structural protein precursor from the nonstructural one is performed by 2A^{pro} (Lian et al., 1982; Toyoda et al., 1986). Viral protease 2A is a multifunctional chymotrypsin-like cysteine protease that catalyzes the cleavage of the viral polyprotein at a tyrosine-glycine pair between the C-terminus of VP1 and its own N-terminus (Rueckert, 1996; Toyoda et al., 1986). Both 2A^{pro} and 3C^{pro} are also responsible for the cleavage of the other cellular proteins such as the eukaryotic Initiation Factor-4G (eIF4G) and the cytoplasmic protein dystrophin. Cleavage of eIF4G (formerly known as p220) leads

* Corresponding author. Fax: +982122431624.

E-mail address: nmaghsouli@sbmu.ac.ir (N. Maghsouli).

Both authors have equally contributed to this manuscript.

